Novel SARS-CoV-2 vaccine candidate SCB-2019 offers good safety profile and elicits strong humoral responses
1. Novel SARS-CoV-2 vaccine SCB-2019 was well-tolerated amongst both younger and older adults. 2. SCB-2019 adjuvanted with AS03 or CpG/Alum ...